Aim The present study aimed to evaluate the effects of Erythrina senegalensi s hydroethanolic extract on diabetes. Methods Six groups of five rats each were used for oral glucose, maltose, and starch tolerance tests. These groups consisted of distilled water, glibenclamide (5 mg/kg) or acarbose (400 mg/kg), and the extract (50, 100, 200, and 400 mg/kg). Diabetes was induced by streptozotocin (55 mg/kg) in 25 Wistar rats, confirmed one week later, and the groups were treated per os as follows: distilled water, insulin, and the extract (100, 200, and 300 mg/kg) for 4 weeks. Hemodynamic parameters were recorded, after which animals were sacrificed, and blood was collected for serum biochemical parameter assays and pancreas was taken for histological examination. In silico study of some compounds identified from E. senegalensis and downloaded from the PubChem database was performed using Molegro Virtual Docker software on HMG‐CoA reductase, NADPH oxidase, and human liver glycogen phosphorylase obtained from the PDB database. Results E . senegalensi s was able to prevent the increase in glycemia and accelerate its decrease. Streptozotocin significantly increased ( p < 0.001) glycemia and serum creatinine, uric acid, triglycerides, total cholesterol, LDL cholesterol, bilirubin, transaminase activity ( p < 0.01), and blood pressure and significantly decreased ( p < 0.001) HDL‐C, proteins, and pancreatic islet in diabetic animals compared to normal animals. The extract improved all the above cited parameters in diabetic rats. In silico, the compounds inhibited HMG‐CoA reductase, NADPH oxidase, and human liver glycogen phosphorylase. Conclusion The extract might exert its antidiabetic effects through its hypoglycemic, antihyperglycemic, hypolipidemic, and antioxidant properties.
Kana et al. (Thu,) studied this question.